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SLEDAIAbstract Background: Neutrophil gelatinase-associated lipocalin (NGAL) is an excellent struc-
tural biomarker for the early diagnosis of acute kidney injury, prognosis, dialysis requirement
and mortality in several common clinical scenarios.
Aim of the work: The aim of this work is to detect the levels of both urinary and serum NGAL in
SLE patients with and without lupus nephritis (LN) and to correlate their levels with renal biopsy
class and disease activity.
Patients and methods: The study included 35 SLE patients; 22 with LN and 13 without as well as
30 matched controls. The SLE Disease Activity Index (SLEDAI) was assessed and the renal biopsy
class determined. Urinary and serum levels of NGAL were assessed by ELISA.
Results: The 35 patients had a median age of 30 years and disease duration of 4 years. They were
31 females and 4 males. The SLE patients had an elevated urinary NGAL (UNGAL) (median
19 ng/ml, IQR 8–87) as compared to controls (median 2 ng/ml, IQR 1–18.3) (p< 0.006). Levels
of UNGAL were higher in patients with LN than those without (p< 0.023). In patients with
LN, serum levels of NGAL were not significantly different from controls (p= 0.6). The UNGAL
level significantly correlated with the renal score of SLEDAI (r= 0.54, p= 0.001) but serum
NGAL level did not (r= 0.25, p= 0.15). UNGAL significantly correlated with grade III and IV
S26 Y. Tawfik et al.of renal biopsy (r= 0.67, p= 0.009). The sensitivity of UNGAL levels for the diagnosis of LN was
85.7%, with a specificity of 80%.
Conclusion: Urinary NGAL is a sensitive marker of proliferative nephritis in SLE and disease
activity.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
SLE is a chronic inflammatory disease of unknown etiology
which can affect the skin, joints, kidneys, lungs, nervous sys-
tem, serous membranes and/or other organs of the body. Main
features of the disease are immunologic abnormalities; the dis-
ease is characterized by the production of auto-antibodies. The
course of SLE is variable and may be associated by periods of
remissions and relapses [1] and could remarkably affect the
quality of life in those patients [2]. Other factors have been
implicated in the pathogenesis of SLE including cytokine
imbalance [3] and gene polymorphisms [4].
One of the most severe manifestations of SLE is lupus
nephritis (LN), which remains a serious cause of morbidity
and mortality, either secondary to kidney disease or to
immunosuppressive drug toxicity [5]. In studies on Egyptian
SLE patients, LN was frequently reported and assessed in rela-
tion to many biomarkers for apoptosis [6], adipocytokines [7],
cartilage degradation [8], oxidative stress [9] and nephritogenic
autoantibodies [10]. Novel markers of renal involvement
including urinary neutrophil gelatinase-associated lipocalin
(UNGAL) have also been assessed in SLE patients [11].
Neutrophil gelatinase-associated lipocalin (NGAL) is a
25 kDa protein of the lipocalin superfamily. This protein is
secreted by immune cells, hepatocytes and renal tubular cells
in several pathological conditions. NGAL has recently gener-
ated great interest as an early marker of renal injury. However,
like many other endogenous biomarkers it is produced by sev-
eral cell types and it exists in several molecular forms. Differ-
ent pathological conditions may be involved in the production
of this molecule [12]. A prominent role of UNGAL was sug-
gested as a potential biomarker of lupus nephritis that could
serially forecast renal disease activity in SLE patients [13].
The aim of the present study was to assess the serum and
urinary NGAL in Egyptian SLE patients with and without
renal involvement and study their relation to other biochemi-
cal parameters, renal biopsy class and disease activity. Detect-
ing its sensitivity, specificity and predictive values for LN in
SLE patients was considered.2. Patients and methods
The present study was carried out on 35 SLE patients; 31
females and 4 males with an age interquartile range (IQR) of
24–37 years (median 30 years). All patients fulfilled the sys-
temic lupus international collaborating clinics (SLICC) classi-
fication criteria for SLE [14]. They were selected from the
outpatient clinics of the Rheumatology and Rehabilitation
and Internal Medicine Departments as well as the Nephrology
Department of the Urology Center (Mansoura University
Hospitals). Patients were grouped according to the presenceor absence of active renal disease or a renal SLE Disease Activ-
ity Index (SLEDAI) score ofP4 and considered with or with-
out LN respectively. Thirty healthy subjects were included as a
control group. This study was approved by the Ethics Com-
mittee of Faculty of Medicine Mansoura University. Written
informed consent was obtained from all participants.
Exclusion criteria: Patients suffering of any of the following
were excluded: Breast tumors, inflammatory bowel diseases,
polycystic kidneys, acute kidney injury (AKI), post-renal
transplantation, chronic heart diseases as there is an increase
in the level of NGAL in these conditions.
All patients were subjected to full history taking and clini-
cal examination. Disease activity in the SLE patient was
detected by the SLEDAI [15]. Renal activity was assessed
using renal SLEDAI which includes four renal elements in
total SLEDAI score namely proteinuria, hematuria, pyuria
and urinary casts. Each item in the renal SLEDAI is scored
4 points; the renal SLEDAI score ranged from 0 to 16. Renal
biopsy was performed to assess the grade of LN for patients
with persistent hypertension, rising creatinine levels, persistent
hematuria, proteinuria, casts. The world health organization
(WHO) classification of LN [16] was used to define the
histopathological lesions.
Assessment of serum and urinary NGAL by ELISA: Urine
and serum samples were concomitantly taken from all patients
immediately after diagnosis. Serum NGAL was measured
using a serum separator tube (SST) and samples were allowed
to clot for 30 min before centrifugation for 15 min at 1000g.
Serum was removed and immediately assayed or aliquot and
sample stored at 620 C. Repeated freeze–thaw cycles were
avoided. For urinary NGAL aseptically collected morning
urine sample (mid-stream) was collected voided directly into
a sterile container. It was then centrifuged to remove particu-
late matter, immediately assayed or aliquot and stored at
620 C. Repeated freeze–thaw cycles were avoided. Human
NGAL was measured using the quantitative sandwich enzyme
immunoassay technique using Human Lipocalin-2/NGAL
Immunoassay [Quantikine, R&D system, Minneapolis,
USA]. A monoclonal antibody specific for Lipocalin-2 has
been pre-coated onto a microplate. Standards and samples
are pipetted into the wells and any Lipocalin-2 present in the
samples bounded by the immobilized antibody. After washing
away any unbound substances, an enzyme-linked monoclonal
antibody specific for Lipocalin-2 is added to the wells. Follow-
ing a wash to remove any unbound antibody-enzyme reagent,
a substrate solution is added to the wells and color develops in
proportion to the amount of Lipocalin-2 bound in the initial
step. The color development is stopped and the intensity of
the color is measured.
Statistical analysis: The clinical and laboratory data were
tabulated, coded then analyzed using the computer program
‘statistical package for social science’ (SPSS) version 17.0.
Table 1 Clinical manifestations of the systemic lupus erythematosus (SLE) patients.
Manifestations n (%) Systemic lupus erythematosus patients
All (n= 35) With LN (n= 22) Without LN (n= 13)
Constitutional 29 (82) 21 (95) 8 (61.5)
Muco-cutaneous 30 (85) 20 (91) 10 (77)
Arthritis 20 (57) 12 (54) 8 (61.5)
Renal 22 (63) 22 (100) 0 (0)
Vasculitis 12 (34) 6 (27) 6 (46)
Cardiac 3 (8) 1 (4.5) 2 (15.4)
Pulmonary 11 (31) 6 (27) 5 (38.5)
Neurological 4 (11) 3 (13.6) 1 (7.7)
Gastrointestinal 17 (48.6) 12 (54.5) 5 (38.5)
LN: lupus nephritis.
Urinary and serum neutrophil gelatinase-associated lipocalin in SLE patients S27Descriptive statistics were calculated for the anthropometric
measurements and laboratory data in the form of: Mean, Stan-
dard deviation (±SD) and interquartile range (IQR). The
significance of difference was assessed using Mann–Whitney
U-test for continuous non-parametric data. To assess correla-
tion between some investigated parameters, Spearman rho test
was used. To detect the sensitivity, specificity, positive predic-
tive value, negative predictive value of UNGAL excretion a
conventional receiver operating characteristic (ROC) curve
was used.Table 2 Laboratory investigations of the systemic lupus erythemat




RBCs (million/mm3) 3.7 ± 0.6
3.7 (3.14–4.1)
Hemoglobin (gm/dl) 10.2 ± 1.4
10 (9.3–11.3)
WBCs (thousands/mm3) 7.4 ± 6.7
5.7 (3.9–8.8)
Platelets (thousands/mm3) 214.6 ± 130.4
201 (122–259.3)
Creatinine (mg/dl) 1.7 ± 1.5
1 (0.7–1.8)
ESR (mm/1st hr) 59.2 ± 45.4
56.5 (16.5–95)
Proteinuria (g/day) 0.81 ± 0.59
0.6 (0.37–1.1)
ANA positivity n (%) 29 (83%)
Anti-ds DNA (IU/ml) 181.25 ± 199.13
127.5 (45.8–240)
C3 (mg/dl) 92.6 ± 18.7
95.5 (74.4–108.1)
C4 (mg/dl) 23.03 ± 7.3
23.2 (17.6–28.6)
LN: lupus nephritis, RBCs: red blood cells, WBCs: white blood cells, ESR
DNA: antidouble stranded DNA, C: complement.3. Results
Thirty-five SLE patients; 31 females and 4 males (F:M 7.8:1)
with an age IQR of 24–37 years (median 30 years) and disease
duration of 1–6 years (median 4 years). Clinical manifestations
and laboratory data of the SLE patients with and without LN
are presented in Tables 1 and 2. The median age of patients
with LN (n= 22) was 27 years (IQR 23–27 years) and those
without (n= 13) was 32 years (IQR 29.5–40.5 years). In
patients with LN they were 20 females and 2 males (F:Mosus (SLE) patients.
us (SLE) patients
With LN (n= 22) Without LN (n= 13)
3.6 ± 0.6 3.9 ± 0.5
3.3 (3.1–4.2) 3.9 (3.6–4.2)
9.95 ± 1.5 10.6 ± 1.1
9.8 (8.9–11.4) 10.95 (9.6–11.3)
6.5 ± 4.2 6.5 ± 2.1
4.8 (3.9–8.9) 6.5 (5.2–8.6)
209.8 ± 88.4 225.3 ± 200.4
201(135.3–255.8) 220 (39.5–352.8)
2.2 ± 1.8 0.9 ± 0.2
1.5 (0.7–3.5) 0.9 (0.8–1)
55.7 ± 47.9 65.1 ± 42.7
43 (10–95) 70 (24–111.5)
1.01 ± 0.53 0.16 ± 0.13
0.8 (0.6–1.5) 0.16 (0.04–0.25)
18 (82%) 11 (85%)
147.3 ± 171.7 240.75 ± 240.57
63.5 (24.5–221.3) 220 (69.5–243.8)
86.5 ± 19.8 102.8 ± 10.8
75.4 (72.1–106.8) 100.1 (95.8–111.7)
21.9 ± 6.7 24.9 ± 8.1
21.2 (17.1–27.4) 24.9 (18.8–31.5)
: erythrocyte sedimentation rate, ANA: antinuclear antibody, Anti-ds
Figure 2 Comparison of serum neutrophil gelatinase associated
lipocalin (NGAL) between systemic lupus erythematosus (SLE)
patients and controls.
S28 Y. Tawfik et al.10:1) while in patients without they were 11 females and 2
males (F:M 5.5:1). In patients with LN the median disease
duration was 3.5 years (IQR 1.75–6 years) and in those with-
out LN was 5 years (IQR 0.75–7 years). Renal biopsy was
done to 14/22 (63.6%) of patients with LN; 3 (21.4%) had
class II LN, 6 (42.9%) had class III and 5 patients (35.7%)
had class IV LN.
A comparison of the urinary and serum NGAL between
SLE patients and control is presented in Figs. 1 and 2 respec-
tively. The urinary NGAL level in SLE patients was signifi-
cantly increased (median 19 ng/ml, IQR 8–87) compared to
that of the controls (median 2 ng/ml, IQR 1–18.3)
(p= 0.006). There was no significant difference between serum
NGAL levels in SLE patients (median 25 ng/ml, IQR 5–102)
and control (median 20 ng/ml, IQR 14.4–35.6) (p= 0.6).
The UNGAL level significantly correlated with the total
SLEDAI (r= 0.54, p= 0.001). A stronger correlation was
found between UNGAL and the renal SLEDAI (r= 0.63,
p= 0.0001). In LN patients, no association was found
between UNGAL and the total SLEDAI (r= 0.32,
p= 0.14) but a very strong correlation was found between
UNGAL and renal SLEDAI (r= 0.9, p= 0.0001). In patients
without LN, no significant correlation was found with the total
or renal SLEDAI. The serum NGAL did not show any signif-
icant correlation with the total SLEDAI (r= 0.25, p= 0.15)
or renal SLEDAI (r= 0.4, p= 0.3). In patients with LN,
there was no significant correlation between serum NGAL
and total SLEDAI (r= 0.16, p= 0.47) but a significant corre-
lation was found with the renal SLEDAI (r= 0.48, p= 0.04).
In patients without LN there was no significant correlation
between serum NGAL and total or renal SLEDAI.
Correlations between urinary NGAL with laboratory
parameters in the SLE patients with and without LN are pre-
sented in Table 3. Correlation between urinary and serumFigure 1 Comparison of urinary neutrophil gelatinase associated
lipocalin (UNGAL) between systemic lupus erythematosus (SLE)
patients and controls.NGAL with renal biopsy showed that UNGAL significantly
correlated with the grade of renal biopsy (r= 0.67,
p= 0.009). No significant correlation was found between
serum NGAL and renal biopsy grades in patients with LN
(r= 0.09, p= 0.77). A significant correlation was found
between urinary and serum NGAL in SLE patients
(p= 0.001) and in those with (p= 0.03) and those without
(0.024) LN.
The cut-off value, sensitivity and specificity of UNGAL in
SLE patients are presented in Fig. 3. At a cutoff value of
18 ng/ml, the sensitivity of UNGAL levels for the diagnosis
of LN was 85.7%, with a specificity of 80%.The area under
the ROC curve (AUC) was 0.93.
4. Discussion
Despite the extensive work done to reveal the underlying
mechanisms responsible for the pathogenesis of SLE, few
biomarkers have been remarkably involved. The lack of reli-
able, specific biomarkers not only delays clinical management
of SLE but also halts development of new therapeutic agent
[17]. LN is considered a real challenge in the management of
SLE patients because of the difficulty in diagnosing its onset
and detecting relapses before serious renal damage has
occurred. NGAL/Lipocalin-2 has been identified to have a role
in the pathogenesis of several disease states in different organ
systems, especially in kidney diseases. Lipocalin-2 may have a
protective role in the context of renal insults through the
induction or prevention of apoptosis by an iron-transport
dependent mechanism [18].
In the present study it has been shown that UNGAL is an
excellent marker of LN activity. The SLE patients have a sig-
nificantly higher level of UNGAL compared to the controls.
Table 3 Correlation between urinary Neutrophil gelatinase associated lipocalin (UNGAL) and laboratory parameters in the systemic
lupus erythematosus (SLE) patients.
Parameter r (p) Urinary NGAL in SLE patients
All patients (n= 35) With LN (n= 22) Without LN (n= 13)
RBCs (106/mm3) 0.34 (0.06) 0.51* (0.016) 0.11 (0.76)
Hemoglobin (gm/dl) 0.28 (0.12) 0.49* (0.02) 0.2 (0.57)
WBCs (103/mm3) 0.04 (0.85) 0.03 (0.9) 0.28 (0.43)
Platelets (103/mm3) 0.01 (0.96) 0.2 (0.38) 0.1 (0.78)
Creatinine (mg/dl) 0.26 (0.21) 0.48 (0.07) 0.02 (0.96)
ESR (mm/1st h) 0.16 (0.45) 0.19 (0.51) 0.39 (0.3)
Proteinuria (g/day) 0.5* (0.01) 0.41 (0.08) 0.03 (0.96)
ANA positivity n (%) 0.09 (0.59) 0.2 (0.3) 0.14 (0.63)
Anti-ds DNA (IU/ml) 0.29 (0.2) 0.29 (0.31) 0.18 (0.67)
C3 (mg/dl) 0.01 (0.96) 0.27 (0.22) 0.01 (0.99)
C4 (mg/dl) 0.03 (0.86) 0.28 (0.2) 0.5 (0.07)
NGAL: neutrophil gelatinase associated lipocalin, LN: lupus nephritis, RBCs: red blood cells, WBCs: white blood cells, ESR: erythrocyte
sedimentation rate, ANA: antinuclear antibody, Anti-ds DNA: antidouble stranded DNA, C: complement.
* Significant at p< 0.05.
Figure 3 Receiver operating characteristic (ROC) curve of
sensitivity and specificity of urinary neutrophil gelatinase associ-
ated lipocalin (UNGAL) for detection of lupus nephritis. At a
cutoff value of 18 ng/ml the sensitivity was 85.7% and specificity
80%. The area under the ROC curve (AUC) was 0.93.
Urinary and serum neutrophil gelatinase-associated lipocalin in SLE patients S29Patients with active LN have significantly higher UNGAL
levels when compared to patients without LN or to control.
However, no significant difference was found between patients
without LN and controls. These findings are similar to those of
other studies [19–22] reporting that UNGAL, but not serum
NGAL, is considered a high quality biomarker for SLE renal
disease. In contrast to our results a wonderful role of plasma
NGAL as a biomarker in LN has been suggested explaining
that kidney injury results in an increase in NGAL expression
in distant organs especially the liver and lung and the over
expressed NGAL protein may be a distinct systemic pool. Also
any kidney injury will affect glomerular filtration rate and
decrease renal clearance of NGAL leading to its further accu-
mulation in systemic circulation [23]. The present results are in
accordance to those of Pitashny et al. [19] who found a weak
correlation of UNGAL with total SLEDAI in SLE patients
and a significant one with renal SLEDAI in SLE patients espe-
cially those with LN. In contrast to our results [24] no correla-
tion was found between UNGAL and SLEDAI score in LN
patients suggesting that its excretion is related to renal damage
rather than to systemic or immune response occurring in the
kidney [24] and was not correlated to renal activity [25]. The
increase in UNGAL levels in LN may result from increased
glomerular protein loss, disturbed reabsorption in the proxi-
mal nephron segment and increased intrarenal production
[26]. Furthermore, the glomerulus may represent a source of
NGAL [26,27]. In our results serum NGAL significantly corre-
lated with the renal SLEDAI in SLE patients with LN. These
results go with the results of others [23,28] suggesting that
serum NGAL correlated with SLEDAI in LN patients indicat-
ing that disease activity affects NGAL plasma level which
might be expressed by damaged tubules to induce re-
epithelialization. This was further supported by the identifica-
tion of NGAL as a regulator of epithelial morphogenesis in
cultured kidney tubules [29]. In a study on Egyptian SLE
patients, there was a significant increase of UNGAL and a
noticeable correlation between UNGAL and laboratory
parameters of renal disease activity as well as with renal SLE-
DAI suggesting UNGAL as a significant predictor for renal
flare [13]. In another study on Egyptian SLE patients, there
was a significant increase in serum UNGAL levels andsignificantly correlated with the renal biopsy class of LN and
was considered an important marker [11].
Urinary NGAL did not correlate with the hematologic lab-
oratory findings in the SLE patients. This was supported by
the findings of another study [20]. However, a significant cor-
relation was present between UNGAL with hemoglobin and
RBC in LN patients. This was not previously reported in stud-
ies on SLE, however a significant correlation was reported
between NGAL and anemia in several other systemic diseases
and chronic inflammatory states [12]. In this study, serum
NGAL significantly correlated with RBCs and hemoglobin.
Similarly, this was reported by another study [19]. NGAL
S30 Y. Tawfik et al.represents a key factor in the regulation of RBC growth [30] and
the ability to suppress erythropoiesis [31]. In patients with
chronic kidney disease (CKD), anemia is caused from the pro-
gressive reduction of the endogenous production of erythro-
poietin. These patients present with high serum and urine
NGAL, making this molecule a promising marker not only
of CKD progression but also a wonderful tool in the manage-
ment of iron deficiency [32].
There was a significant correlation between UNGAL and
24-h urinary protein in all SLE patients but not in those with
LN which is in agreement with the findings of another study on
children with LN [21]. There was no significant correlation
between UNGAL levels and serum creatinine which supports
previous findings [20] that mentioned that the presence of
lipocalin-2 may have a stronger association with acute disease
activity than with the degree of renal insufficiency. In the pre-
sent study no significant correlation was found between serum
NGAL and 24 h urine protein which is in disharmony to the
results of other studies [23,33,34].
In the current study, there were no correlations between the
UNGAL and complement level or anti-dsDNA antibodies. In
disagreement, it has been reported that pathogenic anti-
dsDNA antibodies up-regulate the expression of NGAL in
mesangial cells [35]. A possible explanation found that the levels
of anti-dsDNA antibodies may decrease concurrently with
acute SLE flares due to increased tissue deposition demonstrat-
ing a complex relationship [36]. It has further been recently
postulated that UNGAL predicts renal flare in patients with a
history of biopsy-proven lupus nephritis with a higher sensitiv-
ity and specificity than anti-dsDNA antibody titers [37].
Urinary NGAL showed significant correlation with the
classes of renal biopsy in the patients with LN and at a cutoff
value of (18 ng/ml), the sensitivity was 85.7% and specificity
80%. This is in harmony with the finding of another study
[21] that found UNGAL considerable in detection of class
III and IV LN. At a cutoff value of 20 ng/mg creatinine, the
sensitivity of UNGAL levels for the diagnosis of LN was
57%, with a specificity of 83%.
Our results showed a significant correlation between uri-
nary and serum NGAL in SLE patients. On the contrary, no
significant correlation was found in 2 previous studies [11,14]
explaining that extra renal sources of NGAL are not responsi-
ble for increased urinary levels in LN and that the enhanced
local production results from renal tubular cells or increased
NGAL leakage from glomerular capillaries. Interestingly, it
has recently been shown that UNGAL had the best sensitivity
and specificity as a biomarker for lupus nephritis compared
to other urinary markers including transforming growth
factor-b1, monocyte chemoattractant protein-1 and inter-
leukin 17 [38].
In conclusion, UNGAL significantly correlates with mea-
sures of LN and disease activity and can be considered as a
potential and powerful marker for lupus nephritis in Egyptian
SLE patients. Further longitudinal larger scale studies, includ-
ing more patients and control are recommended to investigate
its role in response to therapy.
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